Docstoc

Market Research Report : Cardiovascular pharmaceuticals Market in India 2011

Document Sample
Market Research Report : Cardiovascular pharmaceuticals Market in India 2011 Powered By Docstoc
					                 Insert Cover Image using Slide Master View
                                Do not distort




Cardiovascular Pharmaceuticals Market - India
September 2011
Executive Summary

                   Cardiovascular pharmaceuticals market in India is valued at INR X bn in 20--
   Market          The market is expected to grow at a CAGR of y% from 20-----
                   CVD segment is the second largest contributor to domestic sales, contributing around x %

                  Drivers:                                         Challenges:
                   Increasing patient base                               Strong competition
  Drivers and
                   Patent expiry of blockbuster drugs                    Competition from complementary and
  Challenges
                   Increasing disposable income
                   Introduction of new drugs
                   Drug value chain
                                                 PLE                     alternative medicines



Drug regulation
 and patents

 Government
                   Phases of clinical trial

                   Patent approvals
                   Reduction in drug prices
                                              SAM
                   Approval and licensing of drugs



                   Changes in tax structure
  initiatives      Control Programmes

                   Highly fragmented market with large number of players
                   Major foreign players in the market include Company 1, Company 2, Company 3 etc
 Competition
                   Major domestic companies include Company 4, Company 5, Company 6 among others




                               CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT                            2
•Introduction
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Market Value Chain, Regulation and
 Patents
•Competition
•Strategic recommendation



      CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT   3
 Indian cardiovascular pharma market is expected to witness
 huge growth in the coming years
 Indian Market – Overview                                                       Market Size and Growth
 • Cardiovascular therapeutic segment belongs to the                            INR bn
   chronic segment (comprising of cardiovascular, anti                       150
                                                                                                                                                                  x6
   diabetics and neuro pshychiatry), which together                                                                           y%
                                                                                                                                                       x5
   account for around A% of the total pharma market                          100                                                        x4
                                                                                                                     x3
                                                                                                       x2
 • Cardiovascular segment is the second largest                                          x1
                                                                               50
  contributor to domestic pharmaceuticals market
  sales, with a share of x%                                                     0
                                                                                      2010        2011e          2012e             2013e           2014e         2015e
          Within the cardiovascular segment, antihypertensive drugs
          account for almost m% of revenue


 • Presently the market has a size of INR X bn and is
                                                         PLE
          Cholesterol lowering drugs account for one third of sales
                                                                                Top Pharmaceutical Segments – 20--
                                                                                            0    2          4    6        8        10        12    14       16   18

   expected to grow at a CAGR of y% from 20-- to 20--
   to reach INR Y bn
 • Annually, B million Indians die of cardiovascular
   diseases                                           SAM                 anti-infectives
                                                                                     CVD
                                                                                   gastro
                                                                                     CNS
                                                                             respiratory
                                                                                diabetes
                                                                                     pain
                                                                                                                     Y5
                                                                                                                     Y6
                                                                                                                     y7
                                                                                                                        Y4
                                                                                                                                                  Y3
                                                                                                                                                            Y2
                                                                                                                                                                  Y%
                                                                                                                                                                   1




                                                                           gynaecology                      Y8
 • According to WHO estimates, by 2020, almost a% of                             urology         y9
                                                                                oncology        Y 10
   cardiac patients worldwide will be Indian

Source:

                                                CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT                                                                    4
Drivers & Challenges - Summary




  Drivers                                                            Challenges
  Increasing patient base                                            Strong competition

  Patent expiry of blockbuster drugs                                 Competition from complementary and
                                                                     alternative medicines

  Increasing disposable income

  Introduction of new drugs




                                 CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT                      5
Government Initiatives – Summary


                             Reduction in drug prices




                                      Government
                                       Initiatives



       Control programs                                             Changes in tax structure




                      CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT                      6
 Major domestic players in the market (1/9)

 Company Snapshot: Company 1
Corporate Information                                                Financial Performance
                                                                     Revenue                       Revenue                Profit
 Headquarters     City 1, State 1
                                                                     INR bn                                               INR bn
                                                                                                   Profit / Loss
 Founded          19--                                              100                                             r4        60
                                                                                             r2              r3
                                                                               r1
                                                                                                                              40
 Products         Product 1, Product 2
                                                                     50
                                                                                                                              20



                                                 E
 Key People       Person X– MD


                                                L
                                                                      0                                                       0



                                               P
                                                                             2008           2009          2010     2011
  Business Highlights



                                             AM
  • Employing around n people, Company 1 is India’s largest pharmaceutical company, having manufacturing facilities in


                                            S
    m countries and serving customers in over n countries
  • In 20--, the company received the USFDA approval to manufacture and market cardiovascular drug Product Y
  • In 20--, the company entered into an alliance with Company X, one of the largest Japanese innovator companies to
    create an innovator and generic pharmaceuticals powerhouse
  • In 20--, Company 1 entered into an in licensing agreement with Company Y, for the marketing of a fixed dose
    combination of Product A and Product B, under the brand name Product C


Source:

                                      CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT                                          7
                    Thank you for the attention
The Cardiovascular Pharmaceuticals Market – India report is part of Netscribes’ Healthcare
Industry Series.
For more detailed information or customized research requirements please contact:
Tamojit Roy                                                                    Gagan Uppal
Phone:    +91 33 4064 6215                                                     Phone:   +91 22 4098 7530
E-Mail:   tamojit.roy@netscribes.com                                           E-Mail:  gagan.uppal@netscribes.com
Research on India is a product of Netscribes (India) Pvt. Ltd. Research on India is dedicated to disseminating information and providing quick
insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries on




About Netscribes
Netscribes is a knowledge-consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
business research, business & corporate intelligence, content-management services, and knowledge-software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one-stop shop designed to fulfil clients’ profitability and growth
objectives.


Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Research on India,
Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the
sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.

                                            CARDIOVASCULAR PHARMACEUTICAL MARKET INDIA 2011.PPT                                                  8

				
DOCUMENT INFO
Description: For the complete report, get in touch with us at : info@netscribes.com Cardiovascular pharmaceuticals market in India is the second largest contributor to domestic pharmaceutical sales, contributing around 15.6%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for cardiovascular drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, patent expiry of popular blockbuster drugs, increase in disposable income and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part has taken initiatives to reduce drug prices, has made certain reforms in the tax structure and has undertaken various control programmes. The market is expected to exhibit steady growth over the next few years. The report begins with the introduction section which offers a brief insight into the major cardiovascular drug classes. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. An analysis of the drivers explains the factors for growth of the industry including increasing patient population, patent expiry of blockbuster drugs, increase in disposable income and introduction of newer and better drugs. The key challenges include strong competition between the different pharma companies and competition from complementary and alternative medicines. The government initiatives section gives analyses the efforts to reduce drug prices, changes in the customs duty structure and the various control programmes undertaken by the Government.